# Fulgent Genetics

Source: https://onco.cc/companies/fulgent-genetics/  
OnCo record `fulgent-genetics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Fulgent Genetics runs genetic tests, including tests for inherited cancer risk, and through its Fulgent Pharma business develops new forms of chemotherapy wrapped in nanoparticles. Its lead medicine, FID-007, is in a trial for advanced head and neck cancer.

## Summary

Fulgent Genetics, Inc. is headquartered in El Monte, California, and listed on Nasdaq as FLGT; its annual report says it was founded in 2011. Its precision diagnostics business offers clinical tests for hereditary cancer among other areas. In 2022 it acquired Fulgent Pharma Holdings, whose therapeutic business develops cancer medicines on a nanoencapsulation and targeted therapy platform. FID-007 is nanoencapsulated paclitaxel, studied in head and neck, ampullary and pancreatic cancer; after a phase 1/1b trial, a randomised phase 2 trial with cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (NCT06332092) began enrolling in 2024. FID-022, nanoencapsulated SN38 with irinotecan in a polyethyloxazoline material, is in a phase 1 trial (NCT06694480). Its first cancer trial registered under the sponsor name Fulgent Pharma LLC., NCT06332092, was posted on ClinicalTrials.gov in March 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Fulgent Pharma
- HQ: El Monte, CA
- Type: diagnostics
- Website: https://www.fulgentgenetics.com/
- Ticker: FLGT

## Notes

- The company website returned HTTP 403 to an automated fetch on 29 October 2026; facts come from the Form 10-K filed on 27 February 2026, read on 29 October 2026.
- The FID-007 phase 1/1b trial predates 2024, so the therapeutic programme did not first enter the clinic in 2024; only the sponsor name Fulgent Pharma LLC. first appears on the registry then.

## Sources

- Official website: https://www.fulgentgenetics.com/
- Fulgent Genetics Form 10-K for 2025 (SEC): https://www.sec.gov/Archives/edgar/data/1674930/000119312526079169/flgt-20251231.htm
- ClinicalTrials.gov: phase 1 trial of FID-022 (NCT06694480): https://clinicaltrials.gov/study/NCT06694480

## Connected records

- cancers: [Recurrent or metastatic head and neck squamous cell carcinoma](https://onco.cc/cancers/recurrent-metastatic-hnscc/)
- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/), [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- trials: [FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma](https://onco.cc/trials/nct06332092/)

---
JSON: https://onco.cc/api/v1/entities/fulgent-genetics.json